177 related articles for article (PubMed ID: 36433941)
1. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities.
Sequera C; Grattarola M; Holczbauer A; Dono R; Pizzimenti S; Barrera G; Wangensteen KJ; Maina F
Cell Death Dis; 2022 Nov; 13(11):994. PubMed ID: 36433941
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
3. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
4. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
5. c-Myc-driven Hepatocarcinogenesis.
Moon H; Park H; Ro SW
Anticancer Res; 2021 Oct; 41(10):4937-4946. PubMed ID: 34593441
[TBL] [Abstract][Full Text] [Related]
6. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
[TBL] [Abstract][Full Text] [Related]
7. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
8. Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma.
Saddic LA; Wirt S; Vogel H; Felsher DW; Sage J
PLoS One; 2011 May; 6(5):e19758. PubMed ID: 21573126
[TBL] [Abstract][Full Text] [Related]
9. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-216b suppresses the cell growth of hepatocellular carcinoma by inhibiting Ubiquitin-specific peptidase 28 expression.
Zhang JF
Kaohsiung J Med Sci; 2020 Jun; 36(6):423-428. PubMed ID: 32053284
[TBL] [Abstract][Full Text] [Related]
11. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
14. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
[TBL] [Abstract][Full Text] [Related]
15. Characterization of MYC-induced tumorigenesis by in situ lipid profiling.
Perry RH; Bellovin DI; Shroff EH; Ismail AI; Zabuawala T; Felsher DW; Zare RN
Anal Chem; 2013 May; 85(9):4259-62. PubMed ID: 23560736
[TBL] [Abstract][Full Text] [Related]
16. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
17. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
[TBL] [Abstract][Full Text] [Related]
18. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
19. STK33 promotes hepatocellular carcinoma through binding to c-Myc.
Yang T; Song B; Zhang J; Yang GS; Zhang H; Yu WF; Wu MC; Lu JH; Shen F
Gut; 2016 Jan; 65(1):124-33. PubMed ID: 25398772
[TBL] [Abstract][Full Text] [Related]
20. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]